Steve Bryson
Steve Bryson writes about the mechanics of Huntington’s disease, focusing on how lab discoveries in genes, proteins, and brain pathways translate into future treatments. He is a science writer for Huntington’s Disease News with a PhD in biochemistry and nearly two decades of experience as a medical scientist, which anchors his coverage in detailed explanations of experimental work. He is also a published author in peer-reviewed scientific journals and a patented inventor, bringing a researcher’s precision to his reporting.
Experimental therapies and disease pathways in Huntington’s
Bryson’s core coverage follows new therapeutic targets and disease pathways in Huntington’s, particularly in mouse and other preclinical models. In a report on blocking an inflammatory pathway in the brain, he covers work on the cGAS-STING signaling cascade, explaining how deleting the cGAS gene or using a small-molecule STING inhibitor reduces brain inflammation and improves motor coordination and balance in Huntington’s model mice. He describes associated benefits such as preserved vulnerable nerve cells, reduced enlargement of the lateral ventricles, and protection against progressive weight loss, tying each outcome back to striatal atrophy and broader disease progression.
He brings the same depth to protein-focused strategies. In a piece on the short huntingtin fragment HTT1a, Bryson explains how this fragment triggers aggregation of mutant huntingtin protein and drives neurodegeneration in mouse models. He details how blocking HTT1a production reduces and delays protein clumping and corrects a portion of abnormal gene changes in the striatum, and he links these findings to CAG repeat length and its impact on HTT1a levels. Across these articles, his reporting distinguishes itself by walking readers through the logic of targeting specific nodes in disease pathways, rather than just stating that a candidate treatment works.
These stories often track early-stage interventions that aim to slow disease onset or progression, and he consistently frames results within the broader search for disease-modifying therapies. His coverage highlights both the biological rationale and the limitations of preclinical evidence, giving a clear sense of where a study sits in the therapeutic pipeline.
Genetic mechanisms and neuronal development
Bryson regularly focuses on genetic and cellular mechanisms that help explain how Huntington’s damages the nervous system. In one article he reports on how excessive CAG repeats—the genetic defect that causes the disease—create new mRNA splice acceptor sites, leading to altered splicing and the production of unexpected proteins that mis-fold and clump. He outlines how these repeats can become embedded in mRNA molecules with AUG start codons, enabling RAN translation and protein formation, and he notes that changing sequences adjacent to the repeats can prevent these events and stop protein clumping. This kind of granular genetic explanation is a recurring feature of his work.
He also covers neuronal development, particularly in juvenile Huntington’s disease. In a stem cell study, Bryson reports that cells derived from juvenile Huntington’s patients show a delay in developing into mature neurons, illustrated by an over-representation of nestin-expressing neural progenitor cells compared with controls. He explains nestin’s role as a marker of early neuron development and discusses how inhibition of the NOTCH pathway reduces the neural progenitor cell population, supporting a delayed development phenotype in the juvenile striatum. These articles underline his interest in connecting molecular and cellular changes to the clinical picture, especially in early-onset disease.
Translational research and funding landscape
Beyond mechanisms, Bryson follows how major research programs are structured and funded. In his coverage of a study of brain development in people at risk for Huntington’s disease, he reports on an $18 million grant from the U.S. National Institutes of Health that allows the project to expand. He uses the story to show how large-scale imaging and developmental studies aim to understand brain changes before symptoms emerge, giving context on why such funding matters for at-risk individuals. This translational focus—linking bench research, long-term cohorts, and resource investment—is a recurring thread that distinguishes his beat from more general health reporting.
Work across neurodegenerative diseases
While Huntington’s is his primary focus, Bryson also writes about research in other neurodegenerative conditions. In Parkinson’s disease, he has covered a trial testing psilocybin and noted that the company sponsoring the study has additional Parkinson’s therapies in Phase 2 clinical development. This work mirrors his Huntington’s coverage in its emphasis on experimental therapeutics and the clinical trial pipeline, showing an interest in how novel compounds and approaches move through development in related disorders.
Underlying all of his reporting is a scientific background that shapes the way he selects and presents stories. He holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto and spent 18 years as a medical scientist, experience that is reflected in his comfort with detailed descriptions of signaling pathways, gene defects, and experimental methods. As a science writer for Huntington’s Disease News, he consistently uses that expertise to translate complex lab findings into clear, structured news pieces focused on what they mean for understanding and ultimately treating neurodegenerative disease.
4 more health journalists.
Abida Tasnim
Abida Tasnim is a health writer for The Daily Star who focuses on clear, practical guidance that helps readers recognise risks early and act before everyday illnesses turn into wider public health problems. She reports on infectious disease prevention, using measles coverage to show how outbreaks start with individual decisions and behaviours, not just hospital statistics. Her work explains what happens during an outbreak and then anchors the story in simple steps people can take, such as avoiding crowded places when symptoms appear, practising good hygiene, and seeking medical advice early. She writes direct, action‑oriented health explainers that turn clinical questions about contagion and disease burden into everyday choices. Across her beat, she stresses early recognition, timely care, and prevention as the foundations of healthier communities.
Adrián Carballo Casla
Adrián Carballo Casla stands out for turning complex cohort data on ageing into clear, food‑level advice on what older adults should eat to protect brain health and slow chronic disease. He is a researcher in nutritional epidemiology focused on ageing and chronic disease prevention and a postdoctoral researcher in geriatric epidemiology at Karolinska Institutet, writing health explainers for The Conversation. He reports on how diet quality, especially Mediterranean and Mind‑style patterns, shapes dementia risk, grey matter loss and neurocognitive ageing, and how healthy versus pro‑inflammatory diets alter multimorbidity trajectories. His articles translate findings on flavonoids, polyphenols, folate, omega‑3 fats and dietary nitrates into specific food choices and small, practical changes. Much of his coverage is anchored in his own studies on multimorbidity, high‑risk older adults and tailored dietary recommendations, often syndicated to other outlets.
Ahmed Elbediwy
Ahmed Elbediwy brings a lab-based understanding of cancer biology and clinical biochemistry to public-facing health reporting, linking drug mechanisms and molecular pathways to everyday choices about medicines and products. He writes for The Conversation on weight-loss injections, cancer overdiagnosis and anti-ageing supplements, focusing on obesity medicine, cancer signalling, screening trade-offs, skincare and supplement science. His pieces on GLP-1 drugs such as Ozempic, Wegovy and Mounjaro explain why some people do not respond, how gut hormones and appetite signals work, and where psychological support and nutrition fit alongside prescriptions. He co-authors explainers on cancer risk and overdiagnosis and on whether supplements can reverse ageing, separating established knowledge from emerging research. An award-winning senior lecturer at Kingston University, he favours clear, structured explainers, careful definition of key terms and evidence-based appraisal over hype.
Amanda Sheppeard
Amanda Sheppeard is a managing editor and health journalist known for long, detailed explainers that connect complex clinical research, disability policy and political narratives with the daily realities of doctors and patients. She works at The Medical Republic across editorial leadership and commercial content while reporting widely on medicine for its specialist titles. Her real beat spans autism, disability policy, autoimmune disease, infectious threats and system pressures in primary care and hospitals. She covers subjects such as autism diagnosis and the NDIS, rheumatology’s clinical shifts, weight-loss agents in rheumatoid arthritis, infection control, antimicrobial resistance and new modalities like CAR T-cell therapy and microneedles. She reports by doing the synthesis inside the story, linking trial design, molecular targets, funding rules and policy changes to concrete decisions and workflows in clinics and hospitals.